These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 27515101)

  • 1. Hepatitis C virus plays hide and seek with neutralizing antibodies.
    Bankwitz D; Pietschmann T
    Hepatology; 2016 Dec; 64(6):1840-1842. PubMed ID: 27515101
    [No Abstract]   [Full Text] [Related]  

  • 2. [Extracellular maturation of hepatitis C virus: a plasma cloak of invisibility].
    Chanut M; Granier C; Cosset FL; Denolly S
    Med Sci (Paris); 2019; 35(8-9):616-618. PubMed ID: 31532369
    [No Abstract]   [Full Text] [Related]  

  • 3. Virus-neutralizing antibodies to hepatitis C virus.
    Wahid A; Dubuisson J
    J Viral Hepat; 2013 Jun; 20(6):369-76. PubMed ID: 23647953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
    Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
    Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing activity and safety of human monoclonal antibodies against hepatitis C virus.
    Abdel Malak CA; Abelhafez TH; Tabll AA; Mashaly MM; El Shenawy R; El-Abd YS; Shaker MH; El-Awady MK
    Hum Antibodies; 2017; 26(3):127-134. PubMed ID: 29036810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
    Anjum S; Wahid A; Afzal MS; Albecka A; Alsaleh K; Ahmad T; Baumert TF; Wychowski C; Qadri I; Penin F; Dubuisson J
    J Infect Dis; 2013 Dec; 208(11):1888-97. PubMed ID: 23908491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22⁺ B cells.
    Tabll A; El Abd Y; El Din NG; El Shenawy R; Abdelhafez TH; El Awady M; El-Mohamady H; Viazov S
    Hum Antibodies; 2013; 22(3-4):55-65. PubMed ID: 24961863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Antibodies to HCV E1E2 by Lectin-Capture ELISA.
    Major M; Law M
    Methods Mol Biol; 2019; 1911():421-432. PubMed ID: 30593642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.
    Vietheer PT; Boo I; Gu J; McCaffrey K; Edwards S; Owczarek C; Hardy MP; Fabri L; Center RJ; Poumbourios P; Drummer HE
    Hepatology; 2017 Apr; 65(4):1117-1131. PubMed ID: 27997681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
    Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
    Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.
    Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK
    J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection.
    Liu L; Fisher BE; Dowd KA; Astemborski J; Cox AL; Ray SC
    J Virol; 2010 May; 84(10):5067-77. PubMed ID: 20200239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus evasion mechanisms from neutralizing antibodies.
    Lorenzo CD; Angus AGN; Patel AH
    Viruses; 2011 Nov; 3(11):2280-2300. PubMed ID: 22163345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
    Bose M; Mullick R; Das S; Das S; Karande AA
    Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein.
    Diotti RA; Sautto GA; Solforosi L; Mancini N; Clementi M; Burioni R
    New Microbiol; 2012 Oct; 35(4):475-9. PubMed ID: 23109015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral escape and the failure of cellular immune responses.
    Klenerman P; Lechner F; Kantzanou M; Ciurea A; Hengartner H; Zinkernagel R
    Science; 2000 Sep; 289(5487):2003. PubMed ID: 11032545
    [No Abstract]   [Full Text] [Related]  

  • 18. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
    Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific immunoglobulin against hepatitis C virus. Why not?
    Piazza M
    Infez Med; 2012 Sep; 20(3):214-6. PubMed ID: 22992564
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference.
    Sautto G; Mancini N; Diotti RA; Solforosi L; Clementi M; Burioni R
    Antiviral Res; 2012 Oct; 96(1):82-9. PubMed ID: 22898087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.